Posted by Michael Wonder on 16 Feb 2023
Health economic assessment of Kimmtrak in disseminated ocular melanoma
16 February 2023 - The assessment applies to Kimmtrak as the sole treatment for adult patients with melanoma in the uveal melanoma that has spread or is inoperable. The patients must also have a special gene called HLA-A*02:01.
In TLV's baseline scenario, the incremental cost per QALY gained is approximately SEK 5.7 million for Kimmtrak compared to the combination treatment with nivolumab and ipilimumab.
